Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”, Multiple Sclerosis Journal, August 2017, SAGE Publications,
DOI: 10.1177/1352458517726384.
You can read the full text:
Contributors
The following have contributed to this page
